Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Beigene Ltd ADR
(NQ:
BGNE
)
163.56
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 24, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Beigene Ltd ADR
< Previous
1
2
...
9
10
11
12
13
14
15
16
Next >
PureTech Health To Test LYT-200 / Tislelizumab Combo In Difficult To Treat Cancer
July 07, 2021
PureTech Health plc (NASDAQ: PRTC) has announced a clinical trial and supply agreement with an affiliate of BeiGene Ltd (NASDAQ: BGNE). The partnership...
Via
Benzinga
Fireworks Display
July 05, 2021
The oil price rose to 76.81/bbl after the OPEC attempt to have a meeting to agree to boost production (and cut prices) was blocked.
Via
Talk Markets
Week In Review: BeiGene Plans $3 Billion IPO On Shanghai STAR Market
July 03, 2021
BeiGene of Beijing has been approved to stage a $3 billion IPO on the Shanghai Star Stock Exchange. It will be the first Chinese biopharma to be listed in Shanghai, Hong Kong, and the US.
Via
Talk Markets
Topics
Initial Public Offering
Exposures
Securities Market
Is This Chinese Biopharma Stock Still a Buy?
June 28, 2021
The pharmaceutical company had a solid first quarter and boasts a nice pipeline.
Via
The Motley Fool
Week In Review: Insilico Closes $255 Million Round For AI Drug Discovery/Development
June 26, 2021
Insilico Medicine, a Hong Kong company devoted to using AI to speed up drug discovery and R&D, closed a $255 million Series C round led by Warburg Pincus. The company is developing its own products and...
Via
Talk Markets
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
China NMPA Approves Tislelizumab in Non-Small Cell Lung Cancer and Hepatocellular Carcinoma
June 23, 2021
From
BeiGene, Ltd.
Via
Business Wire
A Peek Into The Markets: US Stock Futures Signal Higher Start On Wall Street
June 21, 2021
Pre-open movers U.S. stock futures traded higher in early pre-market trade after the Dow Jones tumbled more than 500 points in the previous session. The Chicago Fed National...
Via
Benzinga
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
5 Stocks To Watch For June 21, 2021
June 21, 2021
Some of the stocks that may grab investor focus today are: Amazon.com, Inc. (NASDAQ: AMZN) will remain in focus with the company’s two-day Prime shopping event beginning...
Via
Benzinga
Week In Review: This Week's China Life Science Deals Total Over $2.5 Billion
June 19, 2021
Shanghai's Zai Lab announced a four-drug immunonocology deal with MacroGenics worth over $1.4 billion. Shanghai's HutchMed (formerly Hutchison Chi-Med) is planning to raise $600 million in a Hong...
Via
Talk Markets
BeiGene Announces China NMPA Approval of BRUKINSA® (Zanubrutinib) for the Treatment of Patients with Relapsed or Refractory Waldenström’s Macroglobulinemia
June 18, 2021
From
BeiGene
Via
Business Wire
BeiGene Announces First Patient Dosed in Global Phase 3 Trial of Anti-TIGIT Antibody Ociperlimab in Non-Small Cell Lung Cancer
June 17, 2021
From
BeiGene, Ltd.
Via
Business Wire
Week In Review: Shanghai CARsgen To Raise $400 Million In Hong Kong IPO
June 12, 2021
Shanghai CARsgen Therapeutics is staging an IPO on the Hong Kong Exchange that could raise $400 million to support development of the company's CAR-T portfolio. The shares are scheduled to begin...
Via
Talk Markets
Topics
Initial Public Offering
Exposures
Securities Market
BeiGene Touts Initial Brukinsa Efficacy, Safety Profile For Leukemia, Compared To Imbruvica
June 11, 2021
BeiGene Ltd (NASDAQ: BGNE) revealed an interim analysis of the Phase 3 ALPINE trial evaluating Brukinsa (zanubrutinib) to Johnson & Johnson’s (...
Via
Benzinga
BeiGene Presents Long-Term Efficacy and Safety Results from Three Pivotal Trials of BRUKINSA® (Zanubrutinib) and Tislelizumab at EHA2021
June 11, 2021
From
BeiGene, Ltd.
Via
Business Wire
BeiGene Presents ALPINE Results at EHA2021 Demonstrating Both Efficacy and Safety Advantages of BRUKINSA® (Zanubrutinib) in Head-to-Head Comparison to Ibrutinib in Chronic Lymphocytic Leukemia
June 11, 2021
From
BeiGene, Ltd.
Via
Business Wire
BeiGene, Shoreline Biosciences Ink Development Pact For NK Cell Therapies In Cancer
June 09, 2021
Shoreline Biosciences Inc and BeiGene Ltd (NASDAQ: BGNE) have announced an exclusive worldwide strategic collaboration to develop and commercialize a...
Via
Benzinga
Shoreline Biosciences and BeiGene Announce Strategic Worldwide Collaboration to Develop and Commercialize Genetically Modified Natural Killer (NK) Cell Therapies
June 09, 2021
From
BeiGene, Ltd.
Via
Business Wire
The Daily Biotech Pulse: Hookipa, PDS Biotech Report Positive Data, Ironwood CFO To Depart, Decision Day For Vertex
June 08, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 7) Agios Pharmaceuticals, Inc...
Via
Benzinga
BeiGene Announces Acceptance of a Supplemental Biologics License Application in China for Tislelizumab in Microsatellite Instability-High (MSI-H) or Mismatch Repair-Deficient (dMMR) Solid Tumors
June 07, 2021
From
BeiGene, Ltd.
Via
Business Wire
The Week Ahead In Biotech: Biogen, Alexion And Vertex FDA Decisions, Multiple Conference Presentations On The Deck
June 07, 2021
Biopharma stocks advanced in the truncated week ended June 4 amid the broader market strength. The American Society for Clinical Oncology meeting got underway during the week,...
Via
Benzinga
Exposures
Product Safety
BeiGene Presents Clinical Data from Two Pivotal Trials of Tislelizumab at the 2021 ASCO Annual Meeting
June 04, 2021
From
BeiGene, Ltd.
Via
Business Wire
BeiGene Presents Clinical Data from Two Phase 2 Trials of Pamiparib at the 2021 ASCO Annual Meeting
June 04, 2021
From
BeiGene, Ltd.
Via
Business Wire
BeiGene Announces First Presentation of the Phase 3 ALPINE Trial Comparing BRUKINSA® (Zanubrutinib) to Ibrutinib in Chronic Lymphocytic Leukemia to Be Featured in Presidential Symposium at EHA2021
June 01, 2021
From
BeiGene, Ltd.
Via
Business Wire
Week In Review: LianBio Acquires Two IBD Candidates In $218 Million Deal
May 22, 2021
LianBio, a Princeton-Shanghai company, in-licensed Greater China rights for two inflammatory bowel disease candidates from Landos Biopharma. The $218 million deal includes $18 million upfront and $200...
Via
Talk Markets
BeiGene's Tislelizumab Shows Progression-Free Survival Benefit in Type Of Head & Neck Cancer
May 21, 2021
BeiGene Ltd (NASDAQ: BGNE) has announced topline results from the Phase 3 RATIONALE 309 trial evaluating tislelizumab combined with chemotherapy as a...
Via
Benzinga
BeiGene Announces Positive Topline Results from Phase 3 Trial of Tislelizumab in Combination with Chemotherapy as First-Line Treatment for Recurrent or Metastatic Nasopharyngeal Cancer
May 21, 2021
From
BeiGene, Ltd.
Via
Business Wire
The Week Ahead In Biotech: ASCO Presentations Front And Center, FDA Decisions Due For Scynexis, Liminal And Alkermes
May 31, 2021
After having declined through the first half of the week, biotech stocks staged a recovery to close higher in the trading week ended May 28. Broader market sentiment and company-...
Via
Benzinga
Exposures
Product Safety
BeiGene to Showcase Broad Clinical Portfolio at 2021 ASCO Annual Meeting
May 19, 2021
From
BeiGene, Ltd.
Via
Business Wire
BeiGene's Brukinsa US Application For Expanded Use Under FDA Review
May 19, 2021
The FDA has accepted for review BeiGene Ltd's (NASDAQ: BGNE) supplemental marketing application for Brukinsa (zanubrutinib) for marginal zone lymphoma (MZL)...
Via
Benzinga
Exposures
Product Safety
BeiGene Announces U.S. FDA Acceptance and Priority Review of Supplemental New Drug Application for BRUKINSA® (Zanubrutinib) in Marginal Zone Lymphoma
May 19, 2021
From
BeiGene, Ltd.
Via
Business Wire
< Previous
1
2
...
9
10
11
12
13
14
15
16
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.